BioScrip Beats, Margins Down - Analyst Blog
12 Novembre 2012 - 10:30AM
Zacks
Specialty pharmacy services
provider, BioScrip Inc. (BIOS) reported a loss of
a penny per share from continued operations in the third quarter of
fiscal 2012, flat year over year. However, adjusting for certain
one-time items, earnings per share (EPS) came in at 7 cents, which
breezed past the Zacks Consensus Estimate of a loss of a penny per
share but was in line with the year-ago adjusted EPS. Total revenue
in the reported quarter stood at $170.4 million, up 27.3% year over
year and exceeding the Zacks Consensus Estimate of $160
million.
Earlier in May 2012, BioScrip sold
certain Pharmacy Services assets including the pharmacy mail
operations and the community retail pharmacy stores to
Walgreen (WAG). Following the divestiture,
BioScrip restructured its operating segments from Infusion/Home
Health Services and Pharmacy Services into three new operating
divisions: Infusion Services, Home Health Services and PBM
Services.
In the reported quarter, solid
revenue growth was attributable to a 39.5% rise in Infusion
Services revenue to $125.9 million, and a 4.2% increase in PBM
Services segment revenue to $27.1 million, partially offset by a
1.4% decline in the company’s Home Health Services segment revenues
to $17.3 million. Reimbursement reductions from Medicare and the
state of Tennessee TennCare program resulted in the year-over-year
decline in the Home Health Services segment.
In the reported quarter there was a
48.2% increase in cost of product revenues ($85.6 million) combined
with a 19.3% rise in cost of service revenues ($26.7 million).
Also, shift in the therapy mix in the Infusion Services segment, as
well as a decrease in home health reimbursement rates from certain
government payers led to a huge 603 basis points (bps) contraction
in gross margin to 34.0% in the quarter. Selling, general and
administrative expenses during the quarter surged 10.5% to $46.8
million resulting in a 184 bps drag in adjusted operating margin
for the quarter to 6.6%.
BioScrip exited the quarter with
$67.2 million of cash and cash equivalents. Year-to-date operating
cash flow was $56.9 million compared with $7.0 million in the
comparable year-ago period. This was due to the collection of
accounts receivable retained after the asset sale, net of accounts
payable paid related to those businesses.
In the reported quarter, BioScrip
acquired Illinois-based privately held InfuScience, Inc.,
a provider of alternate site infusion pharmacy services. The
acquisition price was $38.3 million in cash. However, it could
increase by an additional $3 million within 1 year of the
acquisition, depending on the performance of the acquired body. In
2011, InfuScience generated $40.0 million in annual revenues.
Outlook
BioScrip reiterated its fiscal 2012
revenue guidance of $660–$690 million. However, currently the
company is evaluating hurricane Sandy’s impact on the performance
of its Northeast region.
Our Take
While the company demonstrated
strong sales growth during the quarter, the huge pressure on
margins was a matter of concern. However, we believe that the asset
sale will help BioScrip to emphasize more on areas with long-term
growth potential and high returns. With favorable demographic
trends, including an aging population in the U.S., the company is
optimistic about the future prospects of the home health industry.
Additionally, we believe that the recent acquisition improves
the company’s position in the Infusion and Home Health industry
where it has meaningful strength and competitive advantages.
According to the National Home Infusion Association (“NHIA”), U.S.
health care expenditure in the alternate-site infusion therapy
segment currently represents $9–$11 billion a year.
BioScrip retains a short-term Zacks
#3 Rank (Hold). Over the long term, we have a ‘Neutral’
recommendation on the stock.
BIOSCRIP INC (BIOS): Free Stock Analysis Report
WALGREEN CO (WAG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024